Certara, Inc. (NASDAQ:CERT - Get Free Report) insider Patrick F. Smith sold 5,409 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares of the company's stock, valued at $552,503.73. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Certara Trading Up 1.3 %
CERT opened at $11.24 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. Certara, Inc. has a fifty-two week low of $10.35 and a fifty-two week high of $19.87. The firm has a market capitalization of $1.81 billion, a PE ratio of -28.82, a P/E/G ratio of 5.17 and a beta of 1.49. The company's 50-day moving average is $12.19 and its 200 day moving average is $14.76.
Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The business had revenue of $93.31 million during the quarter, compared to analyst estimates of $96.01 million. During the same quarter in the prior year, the company earned $0.10 EPS. The company's revenue was up 3.2% on a year-over-year basis. As a group, research analysts predict that Certara, Inc. will post 0.27 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Certara
Urgent: This election is rigged
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
A number of institutional investors and hedge funds have recently made changes to their positions in CERT. Mubadala Investment Co PJSC purchased a new stake in Certara in the 4th quarter valued at about $169,135,000. Sei Investments Co. increased its stake in Certara by 12.4% in the 1st quarter. Sei Investments Co. now owns 715,514 shares of the company's stock valued at $12,793,000 after buying an additional 79,013 shares during the last quarter. Geneva Capital Management LLC increased its stake in Certara by 15.1% in the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company's stock valued at $78,747,000 after buying an additional 579,349 shares during the last quarter. Wasatch Advisors LP increased its stake in Certara by 23.4% in the 1st quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company's stock valued at $88,056,000 after buying an additional 932,598 shares during the last quarter. Finally, Motley Fool Asset Management LLC increased its stake in shares of Certara by 94.0% during the 1st quarter. Motley Fool Asset Management LLC now owns 96,792 shares of the company's stock worth $1,731,000 after purchasing an additional 46,897 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on CERT shares. Robert W. Baird decreased their price objective on Certara from $19.00 to $18.00 and set a "neutral" rating for the company in a report on Wednesday, August 7th. Barclays cut their price target on shares of Certara from $18.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Friday, June 28th. UBS Group raised shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target on the stock in a research report on Friday, September 27th. JMP Securities reissued a "market perform" rating on shares of Certara in a research report on Wednesday, July 10th. Finally, KeyCorp cut their price objective on shares of Certara from $23.00 to $20.00 and set an "overweight" rating on the stock in a research report on Thursday, July 11th. Six equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, Certara presently has an average rating of "Hold" and an average target price of $17.79.
View Our Latest Report on CERT
About Certara
(
Get Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
